N
PMVP icon

Nuveen’s PMV Pharmaceuticals PMVP Stock Holding History

Nuveen’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-152,959
Closed -$260K – 3398
2024
Q1 		$260K Hold
152,959
– – ﹤0.01% 3126
2023
Q4 		$474K Buy
152,959
+648
+0.4% +$1.72K ﹤0.01% 3021
2023
Q3 		$935K Sell
152,311
-40,073
-21% -$276K ﹤0.01% 2603
2023
Q2 		$1.2M Buy
192,384
+104,287
+118% +$546K ﹤0.01% 2575
2023
Q1 		$420K Sell
88,097
-10,600
-11% -$74.6K ﹤0.01% 2844
2022
Q4 		$859K Sell
98,697
-17,714
-15% -$189K ﹤0.01% 2742
2022
Q3 		$1.39M Sell
116,411
-588
-0.5% -$8.49K ﹤0.01% 2582
2022
Q2 		$1.67M Buy
116,999
+32,515
+38% +$473K ﹤0.01% 2529
2022
Q1 		$1.52M Sell
84,484
-17,488
-17% -$308K ﹤0.01% 2638
2021
Q4 		$2.35M Sell
101,972
-5,293
-5% -$128K ﹤0.01% 2490
2021
Q3 		$3.2M Buy
107,265
+5,865
+6% +$187K ﹤0.01% 2446
2021
Q2 		$3.46M Buy
101,400
+39,542
+64% +$1.32M ﹤0.01% 2437
2021
Q1 		$2.03M Buy
61,858
+11,841
+24% +$467K ﹤0.01% 2611
2020
Q4 		$3.08M Buy
+50,017
New +$1.96M ﹤0.01% 2292

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Nuveen's PMVP Position: Q2 2024 in Review

Nuveen sold out of PMV Pharmaceuticals (PMVP) in Q2 2024, closing a stake of 152,959 shares — an estimated $260K sold.

Nuveen first reported a position in PMVP in Q4 2020 and held it in 14 quarters. The position peaked at $3.46M in Q2 2021. 93 funds tracked by Wall St. Rank hold PMVP as of Q2 2024.

  • Nuveen reported no remaining PMV Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 152,959 PMV Pharmaceuticals shares in Q2 2024, an estimated $260K.
  • Nuveen first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Nuveen's PMV Pharmaceuticals position peaked at $3.46M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.